

Certificate of Analysis

Print Date: Aug 12th 2021

www.tocris.com

Product Name: L-DOPA Catalog No.: 3788 Batch No.: 4

CAS Number: 59-92-7 EC Number: 200-445-2

IUPAC Name: L-3,4-Dihydroxyphenylalanine

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_9H_{11}NO_4$.Batch Molecular Weight:197.19Physical Appearance:White solidSolubility:water to 5 mM

1eq. HCl to 50 mM

Storage: Store at -20°C

Batch Molecular Structure:

2. ANALYTICAL DATA

HPLC: Shows 99.3% purity

¹H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Optical Rotation: $[\alpha]_D = -12.4$ (Concentration = 5, Solvent = 1N HCl)

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 54.82 5.62 7.1 Found 54.73 5.74 7.09

Tel:+1 612 379 2956



Product Information

Print Date: Aug 12th 2021

www.tocris.com

Product Name: L-DOPA Catalog No.: 3788 Batch No.: 4

CAS Number: 59-92-7 EC Number: 200-445-2

IUPAC Name: L-3,4-Dihydroxyphenylalanine

Description:

L-DOPA is an immediate precursor of dopamine, produced by tyrosine hydroxylase. Displays antiParkinsonian activity.

Physical and Chemical Properties:

Batch Molecular Formula: C₉H₁₁NO₄. Batch Molecular Weight: 197.19 Physical Appearance: White solid

Minimum Purity: ≥98%

Batch Molecular Structure:

Storage: Store at -20°C

Solubility & Usage Info:

water to 5 mM 1eq. HCl to 50 mM

CAUTION: L-DOPA rapidly degrades in alkaline solutions

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Pisani and Shen (2009) Levodopa-induced dyskinesia and striatal signaling pathways. Proc.Natl.Acad.Sci.USA 106 2973.